Enanta Pharma (ENTA) Tops Q2 EPS by 18c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.79), $0.18 better than the analyst estimate of ($1.97). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.04 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight